Pfizer/BioNTech say final results show vaccine 95% effective
An illustration picture shows vials with Covid-19 Vaccine stickers attached and syringes with the logo of US pharmaceutical company Pfizer and German partner BioNTech, on November 17, 2020.
AFP/JUSTIN TALLIS

Pfizer/BioNTech say final results show vaccine 95% effective

(Agence France-Presse) - November 18, 2020 - 9:19pm

WASHINGTON, United States — Pfizer and BioNTech said Wednesday that a completed study of their experimental Covid-19 vaccine showed it was 95% effective.

They said the two-dose vaccine had no serious safety concerns and that the companies will apply for emergency use authorization from US regulators "within days."

The announcement came as coronavirus cases are surging in the US and other parts of the world, and boosted hopes for an end to the pandemic that has upended life around the globe.

"The study results mark an important step in this historic eight-month journey to bring forward a vaccine capable of helping to end this devastating pandemic," said Pfizer CEO Albert Bourla.

"With hundreds of thousands of people around the globe infected every day, we urgently need to get a safe and effective vaccine to the world," he added.

Pfizer had said last week after a preliminary analysis that its product was more than 90 percent effective.

On Monday another biotech firm involved in the race to develop a vaccine, Moderna, said its own vaccine was 94.5 percent effective, according to a preliminary analysis.

Pfizer has previously said it expected to contact the US Food and Drug Administration to apply for an Emergency Use Authorization by the third week of November.

The FDA had imposed a requirement on COVID-19 vaccine makers of having at least two months of follow-up with volunteers after their second dose, taken 28 days after the first, in order to ensure the drugs are safe.

Moderna developed its vaccine along with the US National Institutes for Health.

Both vaccines use mRNA (messenger ribonucleic acid) technology to deliver genetic material to the body that makes human cells create a protein from the virus.

This trains the immune system to be ready to attack if it encounters SARS-CoV-2.

Other vaccines that are in late-stage trials, such as one being developed by Johnson & Johnson and another by Oxford University and AstraZeneca, use modified viruses to deliver genetic material for the same purpose.

No mRNA vaccines have ever been approved, but Anthony Fauci, the United States' top infectious disease scientist, told AFP Tuesday the technology had now "established itself."

COVID-19 VACCINES NOVEL CORONAVIRUS PFIZER
As It Happens
LATEST UPDATE: January 14, 2021 - 7:41pm

Pharma giants Sanofi and GSK said on July 29, 2020, that they have agreed to supply Britain with up to 60 million doses of a potential COVID-19 vaccine. The agreement covers a vaccine candidate developed by France's Sanofi in partnership with the UK's GSK and is subject to a "final contract."

This thread collects some of the major developments in the search for a vaccine to ease the new coronavirus pandemic. (Main photo by AFP/Joel Saget)

January 14, 2021 - 7:41pm

Both Pope Francis and his predecessor, former pope Benedict XVI, have received the coronavirus vaccine, the Vatican says on Thursday.

"I can confirm that as part of the Vatican City State vaccination programme to date, the first dose of the Covid-19 vaccine has been administered to Pope Francis and the Pope Emeritus," spokesman Matteo Bruni says. — AFP

January 13, 2021 - 1:25pm

President Joko Widodo receives the first COVID-19 vaccine in Indonesia.  The shot, from China's Sinovac, kicks off the massive immunization campaign in the country dealing with one of most number of cases in the region.

Indonesia opted to secure millions of doses from the Chinese pharmaceutical company whose lack of transparency about its vaccine sparks concerns. While the Philippines ordered 25 million doses, Indonesia secured 125.5 million from Sinovac.

Indonesia is also expecting 50 million doses from Astrazeneca, 150 million from American biotech firm Novovax, 60 million from Sinopharm and 20 million from CanSino, making it the third territory in the world with the most number of confirmed doses after Europe and the United States. (Handout photo)

January 13, 2021 - 7:17am

The Chinese-developed Coronavac COVID-19 vaccine has demonstrated a 50 percent efficacy following tests in Brazil, the organization in charge of its production in the South American country says.

Coronavac has been given to frontline health care workers in close contact with coronavirus patients.

The Butantan Institute repeated its claim from last week that the vaccine is 78% effective in preventing mild cases that needed treatment and showed 100% efficacy in staving off moderate to serious cases. — AFP

January 12, 2021 - 9:03pm

Switzerland gives the green light Tuesday to the Moderna vaccine against the new coronavirus — the second jab it has authorised for use, joining the vaccine produced by Pfizer-BioNTech.

The Swissmedic regulatory authority said the vaccine from US firm Moderna had shown a "high efficacy rate", and could be deployed immediately.

The neighbouring European Union gave its approval to the Moderna vaccine last Wednesday, with Britain doing likewise on Friday. —  AFP

January 12, 2021 - 5:28pm

AstraZeneca and Oxford University have applied for authorisation for their coronavirus vaccine in the EU with a decision possible by January 29, the European Medicines Agency says on Tuesday.

The jab would be the third available for the 27-nation European Union after the Pfizer-BioNTech and Moderna drugs, as the bloc struggles to speed up the rollout.

"EMA has received an application for conditional marketing authorisation for a COVID-19 vaccine developed by AstraZeneca and Oxford University," the Amsterdam-based regulator says in a statement. —  AFP

Philstar
  • Latest
Latest
Are you sure you want to log out?
X
Login

Philstar.com is one of the most vibrant, opinionated, discerning communities of readers on cyberspace. With your meaningful insights, help shape the stories that can shape the country. Sign up now!

FORGOT PASSWORD?
SIGN IN
or sign in with